Q1 EPS Forecast for Sage Therapeutics Boosted by Analyst
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
Truist Financial Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
Truist Financial analyst Joon Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...
Scotiabank Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), with a ...
pharmaphorum3d
Sage sues Biogen after unsolicited takeover bid
Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...
pharmaphorum5d
Biogen bags rights to epilepsy drug from Stoke in $550m deal
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
ucdavis.edu5d
Translating Innovation to Impact
George Baxter has a Ph.D. in organic chemistry, but he was not made for life in the lab. Baxter’s role is expanding the ...
ThePrint10h
SAGE Group to invest Rs 1,450 cr in Madhya Pradesh, expanding in renewable energy & hospitality says CMD
SAGE Group, a business conglomerate, has announced a significant investment of Rs 1,450 crore in Madhya Pradesh. The ...